Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotinamide versus sevelamer hydrochloride for phosphate control in chronic hemodialysis patients
2008-004673-17Phase 3Active
- Sponsor
- CHU Amiens-Picardie
- Start
- Sep 2008
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3 trial of Nicobion and sevelamer carbonate in hyperphosphatemia and chronic kidney disease-mineral and bone disorder (CKD-MBD) (2 arms), sponsored by CHU Amiens-Picardie. Primary endpoint: Percentage of patients achieving target serum phosphate. Started Sep 2008; status: active.
02
Drugs
Nicobionsevelamer carbonate
03
Conditions
hyperphosphatemiachronic kidney disease-mineral and bone disorder (CKD-MBD)
Beyond the preview
Go deeper on 2008-004673-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004673-17.